Inotuzumab (Besponsa) will be available on the PBS from 1 May for patients with acute lymphocytic leukaemia (ALL). The new PBS listing for the an anti-CD22 antibody Therapy, announced as part of the 2019 Federal Budget, will be for the treatment of relapsed or refractory CD22 positive B-cell precursor ALL. The listing will mean that ...
Inotuzumab listed on PBS for ALL
3 Apr 2019